LEMO is honored to have the support and experience of an exceptional Board of Directors. These generous individuals help set the strategy and direction of key LEMO initiatives. We continue to expand our reach as a result of their counsel and commitment.

LEMO is honored to have the support and experience of an exceptional Board of Directors. These generous individuals help set the strategy and direction of key LEMO initiatives. We continue to expand our reach as a result of their counsel and commitment.

Mike Moran has specialized in providing Commercial Real Estate services to institutional investors and corporate tenants in the San Francisco Bay Area since 1985. On top of representing such Institutional Investors as Prudential, Starwood Capital, Equity Office and Cornerstone- Mass Mutual, Mike has extensive experience with ground up construction, development planning, and lease workouts. On the tenant side, Mike provides relocation services to the likes of Nintendo, California Society of CPA’s, Birkshire Hathaway (Applied Underwriters), Webcor Builders and more. To date, Mike has completed over 15,000,000 square feet of Leases and 5,000,000 square feet of Sales collectively totaling more than $2 billion in transaction volume.

Background & Experience
Cassidy Turley, 1994-Present
Cornish & Carey, 1985-1994
Played for Cal Football 1981-1982

Education
Bachelor's degree, University of California, Los Angeles

Professional Recognition
SIOR Top Office Sales Award - Northern California Chapter, 2012
2011 #1 CoStar Deal Maker for San Mateo County

Community Leadership
Board Member-California Trout Organization 2003, 2004
St. Raymond's Men's Club 2006-present
Board Member, LEMO Foundation 2012-present

Patrick Enright is a founder and Managing Director of Longitude Capital. He focuses on investments in biotechnology.

From 2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member responsible for the Delta Opportunity Fund, where he invested in privately-held and publicly-traded biotechnology companies. Mr. Enright began his investment career at PaineWebber Development Corporation, a direct investment group focused primarily on biotechnology companies. Mr. Enright also has significant life sciences operations experience including senior executive positions at Valentis, Boehringer Mannheim Pharmaceuticals (now Hoffmann-La Roche) and Sandoz (now Novartis).

He currently serves on the boards of CardioDx, Corcept Therapeutics (NASDAQ: CORT), InfaCare Pharmaceuticals, Jazz Pharmaceuticals (NASDAQ: JAZZ) and Xanodyne Pharmaceuticals. He has previously served on the boards of Codexis (NASDAQ: CDXS), Horizon Therapeutics (acquired), MAP Pharmaceuticals (NASDAQ: MAPP), Prestwick Pharmaceuticals (acquired), Threshold Pharmaceuticals (NASDAQ: THLD) and Sequenom (NASDAQ: SQNM).

Mr. Enright holds an M.B.A. from the Wharton School of Business at the University of Pennsylvania and a B.S. in Biological Sciences from Stanford University